411 related articles for article (PubMed ID: 3713831)
1. Replacing the complementarity-determining regions in a human antibody with those from a mouse.
Jones PT; Dear PH; Foote J; Neuberger MS; Winter G
Nature; 1986 May 29-Jun 4; 321(6069):522-5. PubMed ID: 3713831
[TBL] [Abstract][Full Text] [Related]
2. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antigen binding and idiotypic expression by antibodies with polyglycine-replaced complementarity-determining regions.
Sompuram SR; Den W; Sharon J
J Immunol; 1996 Feb; 156(3):1071-81. PubMed ID: 8557981
[TBL] [Abstract][Full Text] [Related]
4. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.
Eigenbrot C; Randal M; Presta L; Carter P; Kossiakoff AA
J Mol Biol; 1993 Feb; 229(4):969-95. PubMed ID: 8095303
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
[TBL] [Abstract][Full Text] [Related]
6. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity.
Cacia J; Keck R; Presta LG; Frenz J
Biochemistry; 1996 Feb; 35(6):1897-903. PubMed ID: 8639672
[TBL] [Abstract][Full Text] [Related]
7. Structural consequences of humanizing an antibody.
Holmes MA; Foote J
J Immunol; 1997 Mar; 158(5):2192-201. PubMed ID: 9036965
[TBL] [Abstract][Full Text] [Related]
8. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops.
Xiang J; Sha Y; Jia Z; Prasad L; Delbaere LT
J Mol Biol; 1995 Oct; 253(3):385-90. PubMed ID: 7473721
[TBL] [Abstract][Full Text] [Related]
9. Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs.
Potter KN; Li Y; Capra JD
J Immunol; 1996 Oct; 157(7):2982-8. PubMed ID: 8816406
[TBL] [Abstract][Full Text] [Related]
10. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
11. Use of human germline genes in a CDR homology-based approach to antibody humanization.
Hwang WY; Almagro JC; Buss TN; Tan P; Foote J
Methods; 2005 May; 36(1):35-42. PubMed ID: 15848073
[TBL] [Abstract][Full Text] [Related]
12. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.
Knappik A; Ge L; Honegger A; Pack P; Fischer M; Wellnhofer G; Hoess A; Wölle J; Plückthun A; Virnekäs B
J Mol Biol; 2000 Feb; 296(1):57-86. PubMed ID: 10656818
[TBL] [Abstract][Full Text] [Related]
13. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
14. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
15. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
16. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.
Sidhu SS; Li B; Chen Y; Fellouse FA; Eigenbrot C; Fuh G
J Mol Biol; 2004 Apr; 338(2):299-310. PubMed ID: 15066433
[TBL] [Abstract][Full Text] [Related]
17. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
Ulrich HD; Schultz PG
J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
[TBL] [Abstract][Full Text] [Related]
18. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies.
Rothe C; Urlinger S; Löhning C; Prassler J; Stark Y; Jäger U; Hubner B; Bardroff M; Pradel I; Boss M; Bittlingmaier R; Bataa T; Frisch C; Brocks B; Honegger A; Urban M
J Mol Biol; 2008 Feb; 376(4):1182-200. PubMed ID: 18191144
[TBL] [Abstract][Full Text] [Related]
19. SDR grafting--a new approach to antibody humanization.
Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion.
Wiens GD; Heldwein KA; Stenzel-Poore MP; Rittenberg MB
J Immunol; 1997 Aug; 159(3):1293-302. PubMed ID: 9233625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
